<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220212054002N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-14</date_registration>
      <primary_sponsor>Mansoura university</primary_sponsor>
      <public_title>External Oblique Intercostal Plane Block  in Supra-umbilical Surgical Incisions</public_title>
      <acronym>EOIB</acronym>
      <scientific_title>External Oblique Intercostal Plane Block Versus rectus sheath Plane Block in Supra-umbilical Surgical Incisions; Randomized Controlled Double Blinded Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71962</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Enrolled  patients will randomly allocated to  group (EOIB) and group (RSB) with allocated ratio 1:1 .Randomization will done before surgery by computer generated random ,Version28.0 . Opaque sealed sequentially numbered envelopes containing the patients` codes will used and opened just before anesthesia by physician who will not involved in the study . The patients will be allocated to either group “EOIB”, who receive external oblique intercostal plane  block , or  group “RSB” who receive rectus sheath plane block , with general anesthesia, Blinding description: Anesthesiologist who will perform the block will not be blinded to group assignment. However,  participant ,anesthesiologist responsible of the patient , and health care providers who collected the data will be blinded to group allocation.</study_design>
      <phase>4</phase>
      <hc_freetext>Post operative pain control in super umbilical surgical incision.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an inplane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine1% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. Intervention 2: Intervention group: The rectus sheath block was performed bilaterally with real-time ultrasonographic guidance (HFL38x/13-6 MHz Linear Array Transducer; Sonosite M-Turbo™, Bothell, WA, USA) using a 22G (0.70 mm × 50 mm)Stimuplex® A insulated needle (B. Braun, Melsungen, Germany) via an in-plane approach to the rectussheath. 10 mL of 1% lignocaine, together with adrenaline 1:200,000, and 10 mL of 0.5% bupivacainewere deposited in the potential space between the rectus abdominis muscle and the posterior rectussheath bilaterally . A total of 30 mL of 1% lignocaine (200 mg) and 20 mL of 0.5% bupivacaine (100 mg)were administered.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all collected identified IPD

When:
6 month after publication

To whom:
only available for people working in academic institutions

Conditions:
IPD and primary outcome

Where to obtain:
zenatddd@gmail.com

How to obtain:
email request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zenat Eldadamony</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Algomhoria street</address>
        <city>Mansoura</city>
        <country1>Egypt</country1>
        <zip>35511</zip>
        <telephone>+20 122 543 9066</telephone>
        <email>zenatddd@gmail.com</email>
        <affiliation>Mansoura university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zenat Eldadamony Mohamed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Algomhoria street</address>
        <city>Mansoura</city>
        <country1>Egypt</country1>
        <zip>35511</zip>
        <telephone>+20 100 726 8585</telephone>
        <email>zenatddd@gmail.com</email>
        <affiliation>Mansoura university</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Egypt</country2>
    </countries>
    <criteria>
      <inclusion_criteria>American Society of Anesthesiologists (ASA) physical status grade I -II
Scheduled to undergo elective supra-umbilical surgeries under GA (epigastric herniotomy- gastrectomy-open cholecystectomy- nephrectomy).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to local anesthetics,,
Infection at the site of injection,
Coagulopathy,
Chronic pain syndromes
Prolonged opioid medication,
Chronic liver disease , or chronic renal disease,
cognitive impairment.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K87</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>umbilical surgical incision</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an inplane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine1% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.</i_keyword>
      <i_keyword>Intervention group: The rectus sheath block was performed bilaterally with real-time ultrasonographic guidance (HFL38x/13-6 MHz Linear Array Transducer; Sonosite M-Turbo™, Bothell, WA, USA) using a 22G (0.70 mm × 50 mm)Stimuplex® A insulated needle (B. Braun, Melsungen, Germany) via an in-plane approach to the rectussheath. 10 mL of 1% lignocaine, together with adrenaline 1:200,000, and 10 mL of 0.5% bupivacainewere deposited in the potential space between the rectus abdominis muscle and the posterior rectussheath bilaterally . A total of 30 mL of 1% lignocaine (200 mg) and 20 mL of 0.5% bupivacaine (100 mg)were administered.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>POST OPERATIVE PAIN SCORE. Timepoint: 24 hours post operative. Method of measurement: VISUAL ANALUGE SCALE.</prim_outcome>
      <prim_outcome>Amount of postoperative morphine consumed. Timepoint: 24 hours post operative. Method of measurement: milligram.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Amount of postoperative morphine consumed. Timepoint: 24 hours post operative. Method of measurement: milligram.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mansoura university  hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-06</approval_date>
        <contact_name>Institutional Research Board</contact_name>
        <contact_address>Algomhorea street Mansoura Mansoura Egypt</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
